US schizophrenia drug market is estimated to grow significantly at a CAGR of 2.7% during the forecast period. This growth is backed by the presence of well-developed healthcare infrastructure and awareness for mental health. The first Wednesday in November each year is celebrated as National Stress Awareness Day in the country and on the day various programs are conducted to create awareness related to the treatment available for the management of schizophrenia. As per the National Alliance on Mental Illness, nearly 40 million people in the US representing 19.1% of the total US population experience an anxiety disorder in any given year. Around 8% of children and teenagers experience an anxiety disorder. Most of the people experience developing symptoms of anxiety disorder before the age of 21. Moreover, the presence of major market players in the US is projected to make a significant contribution to the growth of the schizophrenia drug market in the country. Lupin Ltd., Pfizer, Inc., others are the major providers of schizophrenia drugs, devices, and therapies in the country. These companies are constantly focusing on making advancements in their product offerings to offer quality products. 

Visit for Global Schizophrenia Drugs Market Report at: https://www.omrglobal.com/industry-reports/schizophrenia-drugs-market

US schizophrenia drug market is classified on the basis of therapeutic class and treatment. Based on therapeutic class, the market is segmented into second-generation antipsychotics, third-generation antipsychotics, and other therapeutic classes. Among these therapeutic classes, the second-generation antipsychotics are majorly used in therapeutic classes for the treatment of schizophrenia. Based on treatment, the market is bifurcated into oral and injectables. The oral treatment solution dominates the US schizophrenia drug market due to the presence of a large number of drug manufacturing companies in the country.

The companies which are contributing to the growth of the US schizophrenia drugs market include Allergan PLC, Catalent, Inc., Otsuka Pharmaceutical Co., Ltd., Eli Lilly and Co., AstraZeneca PLC, and Johnson & Johnson Services, Inc. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, funding to the start-ups, and technological advancements to stay competitive in the market. 

Research Methodology

The market study of the US schizophrenia drug market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior, and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.

Secondary Sources Include

• Financial reports of companies involved in the market.
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalog.

The report provides an in-depth analysis of market size, various services offered by the players, and market opportunity. The report will serve as a source for 360-degree analysis of the market delivering insights for making better business decisions.

Market Segmentation

1. US Schizophrenia Drugs Market Research and Analysis by Therapeutic Class
2. US Schizophrenia Drugs Market Research and Analysis by Treatment

The Report Covers

• Comprehensive research methodology of the US schizophrenia drug market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• An exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the US schizophrenia drug market.
• Insights about market determinants which are stimulating the US schizophrenia drug market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.